Mounjaro Skin Sensitivity: Label Rates, Skin Pain and When to Call a Doctor

Start with our pillar guide: How to Fix Ozempic Face: What the Evidence Supports (2026), or browse all GLP-1 & Skin articles.

Mounjaro skin sensitivity covers 3 different things on the tirzepatide label: hypersensitivity reactions such as hives and eczema (3.2% vs 1.7% on placebo), injection-site reactions (3.2% vs 0.4%), and dysesthesia, which is burning or painful skin with no rash (0.4%). Hair loss is listed too. Evidence: well-established as label-listed adverse reactions.

Never stop, skip or change a GLP-1 medication for skincare reasons. Talk to your prescriber first.

Key takeaways

• The FDA label for Mounjaro (tirzepatide) reports hypersensitivity reactions in 3.2% of people on the drug vs 1.7% on placebo, and injection-site reactions in 3.2% vs 0.4% (Mounjaro label).
• When skin "hurts to touch" with no rash, the label term is dysesthesia. It is a sensory symptom, not damage to the skin barrier. In a large semaglutide trial it was mostly mild and usually cleared up while people kept taking the drug (Wharton et al., 2025).
• Hair loss happened in 4–5% of people on Zepbound (tirzepatide) vs 1% on placebo (Zepbound label).
• No topical product, peptides included, has been tested in people taking GLP-1 medications.
• Rash with swelling of the face, lips or throat, or any trouble breathing or swallowing, is an emergency.

Mounjaro skin sensitivity is a common worry in tirzepatide communities. One question comes up again and again: skin that feels sunburned or sore after a shot even though nothing is visible. This guide sorts the label-listed skin reactions by type, gives the trial numbers behind each one, and explains which symptoms need a clinician. For the broader routine, see our GLP-1 skincare protocol guide.

Mounjaro and Zepbound contain the same drug, tirzepatide, which acts on both the GIP and GLP-1 receptors. Mounjaro is approved for type 2 diabetes and Zepbound for weight management, so this article draws on both labels.

What is Mounjaro skin sensitivity?

Mounjaro skin sensitivity isn't one diagnosis. It's a catch-all phrase people use for at least 3 different label-listed reactions: an immune reaction (hypersensitivity), a local reaction where the needle goes in, and a nerve-type sensation called dysesthesia.

The 3 differ in how they look, where they show up and what to do about them:

The old version of this article described a "barrier-related" type of sensitivity caused by eating less fat. We removed it. No study links tirzepatide to a damaged skin barrier, higher water loss through the skin, or essential fatty acid deficiency.

How common are Mounjaro skin side effects, according to the label?

The labels give exact rates from placebo-controlled trials. These are trials in which some participants got an inactive injection, so you can see how much of each reaction is above the background rate.

Hypersensitivity reactions on Mounjaro

The Mounjaro label reports hypersensitivity reactions in 3.2% of tirzepatide-treated patients vs 1.7% on placebo. The label notes these reactions were "sometimes severe (e.g., urticaria and eczema)" (Mounjaro label, NDA215866). Evidence: well-established (pooled placebo-controlled trials).

The same label breaks the rate down by anti-drug antibodies, which are immune proteins some people make against the medicine itself. Hypersensitivity occurred in 4.1% of patients who developed anti-tirzepatide antibodies and 3.0% of those who did not (Mounjaro label).

On Zepbound, most hypersensitivity reactions were skin reactions such as rash and itching (Zepbound label, NDA217806).

Injection-site reactions on Mounjaro and Zepbound

The Mounjaro label reports injection-site reactions in 3.2% of tirzepatide patients vs 0.4% on placebo (Mounjaro label). In the Zepbound weight-management trials (SURMOUNT-1 and -2), injection-site reactions occurred in 6–8% of people on tirzepatide vs 2% on placebo (Zepbound label). Evidence: well-established.

The Zepbound label also links these reactions to antibodies. Injection-site reactions occurred in 11.3% of people with anti-drug antibodies vs 1% of those without (Zepbound label).

Dysesthesia rates on tirzepatide

The Mounjaro label lists dysesthesia at 0.4% at each dose (Mounjaro label). The Zepbound label lists it at 0.2%, 0.2% and 0.4% for the 5, 10 and 15 mg doses vs 0.1% on placebo (Zepbound label). Evidence: well-established as a label-listed reaction. These are low rates.

Label versions: Mounjaro effective 2026-07-29; Zepbound effective 2026-08-28; both retrieved through the openFDA drug label API on Oct 10, 2026.

A 2026 narrative review of tirzepatide's effects on skin reached a similar picture. It lists hypersensitivity, injection-site reactions and rare severe events as the documented skin effects (El-Amawy et al., 2026, Anais Brasileiros de Dermatologia; narrative review; funding not reported in the abstract). An earlier version of this article said that review appeared in JAAD. That was wrong, and we've corrected it.

Why does skin hurt to touch on Mounjaro?

When skin burns, tingles or hurts to light touch with no rash, the label term is dysesthesia. It describes a change in how skin feels, not a change in the skin itself, so moisturizers and barrier creams aren't a targeted fix.

A few terms help when you talk to a clinician:

• Dysesthesia: an unpleasant, abnormal sensation such as burning or soreness with no visible cause.
• Allodynia: pain from a touch that normally wouldn't hurt, like clothing or bedsheets.
• Paresthesia: tingling or a pins-and-needles feeling.
• Hyperesthesia: heightened sensitivity to touch.

The Wegovy (semaglutide) label groups all of these, along with "skin burning sensation," "pain of skin" and "sensitive skin," under dysesthesia (Wegovy label, DailyMed). Many people describe exactly this as "skin sensitivity."

What the largest trial shows about GLP-1 skin pain

The best data on this symptom come from a semaglutide trial, not a tirzepatide trial. STEP UP was a 72-week, double-blind phase 3b RCT of 1,407 adults that compared semaglutide 7.2 mg, semaglutide 2.4 mg and placebo. It was sponsored by Novo Nordisk (Wharton et al., 2025).

In STEP UP, dysesthesia was reported by 22.9% of participants on semaglutide 7.2 mg, 6.0% on 2.4 mg and 0.5% on placebo. Those figures come from the Lancet Diabetes & Endocrinology abstract page, not the PubMed abstract text (Wharton et al., 2025). Weight loss was 18.7%, 15.6% and 3.9% respectively. Evidence: limited to moderate (1 large RCT, sponsor-run).

The current Wegovy label shows the same dose pattern. In the 7.2 mg trial table, dysesthesia was 0% on placebo, 6% on 2.4 mg and 22% on 7.2 mg, and it is now listed among the most common adverse reactions (5% or more) (Wegovy label).

The tirzepatide label rates (0.2–0.4%) are much lower than the semaglutide 7.2 mg figure. Different trials collect and group symptoms differently, though, so these numbers can't be used to say one drug causes more skin pain than the other. No head-to-head trial has compared skin symptoms between Mounjaro and Ozempic.

The pattern people describe

In Mounjaro and Zepbound communities, a recurring report is skin that feels sunburned or bruised with no rash. People often notice it after the first dose or a dose increase. It usually lasts a day or two but sometimes comes back for months, and many people aren't sure whether it's worth mentioning to their doctor. It is worth mentioning, because it's a recognized, label-listed reaction your prescriber can track.

Does Mounjaro skin sensitivity go away?

For dysesthesia, the trial data point toward yes for most people: in STEP UP it was mostly mild and usually resolved while participants stayed on treatment. For hypersensitivity and injection-site reactions, no tirzepatide-specific data on duration are available, so how long they last is a question for your prescriber.

Novo Nordisk's ADA 2025 poster on STEP UP reported that dysesthesia events were mostly mild, none were classified as serious, and about 86% resolved during treatment (STEP UP, Wharton et al., 2025; sponsor poster data, not in the PubMed abstract). Evidence: limited (sponsor-reported, semaglutide only).

We removed the old article's claims that sensitivity "responds within 2–6 weeks" to a skincare routine or "does not resolve on its own." Neither claim had a source, and the second contradicts the STEP UP data.

Does Mounjaro cause hair loss?

Hair loss is a label-listed reaction to tirzepatide. In the Zepbound trials it occurred in 4–5% of people vs 1% on placebo, and the Mounjaro label lists alopecia among post-marketing reports (Zepbound label; Mounjaro label).

A 2026 meta-analysis pooled 9 interventional studies (7 of them RCTs) covering 4,114 people taking GLP-1 medications. It found a hair-loss risk ratio of 3.25 vs placebo (95% CI 1.44–7.36) and a pooled event rate of 3.9% (Cheng et al., 2026; duration not reported in the abstract; authors declared no competing interests). Evidence: well-established.

A common question is whether the drug causes the shedding or the fast weight loss does. The Wegovy label describes hair loss as "associated with weight reduction" (Wegovy label), but no study has fully separated the two for tirzepatide. For timelines, FDA report trends and what helps, see our tirzepatide hair loss guide. Weight loss can also leave marks on body skin; see stretch marks after weight loss.

What do FDA adverse event reports show about Mounjaro skin sensitivity?

FAERS, the FDA Adverse Event Reporting System, contains thousands of reports listing tirzepatide alongside skin symptoms. These reports confirm that people are noticing these symptoms. They can't tell you how common the symptoms are or whether the drug caused them. Our FDA data study on semaglutide and tirzepatide skin and hair reports breaks these reports down by symptom and by quarter.

FAERS reports show what patients and clinicians reported while on a drug. They don't show that the drug caused the event, and they can't be used to estimate how often it happens. Reports are voluntary and unverified. Counts rise with the number of people using a drug and with media attention, and the data include duplicate reports and have no denominator (no count of total users).

How we got this data: We queried the openFDA drug event API for the generic name "TIRZEPATIDE" combined with each MedDRA preferred term below, and read the total result count. Query run Oct 10, 2026, 2:29 PM CT. Counts include reports listing tirzepatide in any role. Tirzepatide had 160,663 total reports.

Source: openFDA FAERS, queried Oct 10, 2026. Reports, not confirmed drug effects.

For context, the label puts tirzepatide dysesthesia at 0.2–0.4% in controlled trials. A 2025 FAERS review of 6 GLP-1 medications, including tirzepatide, found the most-reported skin reactions were eczematous reactions, pruritus, drug eruptions, hyperhidrosis (excess sweating) and alopecia. Life-threatening events made up 2.17% of skin-related reports (Daniel et al., 2025; pharmacovigilance review; funding not reported in the abstract). Evidence: pharmacovigilance only, so no causation.

When is Mounjaro skin sensitivity a reason to call a doctor?

Some symptoms need emergency care: a rash or hives together with swelling of the face, lips, tongue or throat, trouble breathing or swallowing, or feeling faint. Call 911 or go to an emergency department. Report other skin symptoms to your prescriber, even mild ones.

Seek emergency care for: - Swelling of the lips, eyes, tongue or throat. This deeper swelling is called angioedema. - Trouble breathing or swallowing, wheezing or throat tightness - Dizziness, fainting or a racing heart along with hives - Blistering, peeling or a rapidly spreading rash

The Wegovy label reports serious hypersensitivity reactions, including anaphylaxis and angioedema, with semaglutide (Wegovy label). The Mounjaro label notes that hypersensitivity reactions were sometimes severe (Mounjaro label).

Contact your prescriber soon about: - Hives or rash anywhere on the body - Injection-site reactions that grow, spread or don't settle - Skin burning, tingling or pain that recurs or interferes with sleep or clothing - Noticeable hair shedding

Never stop, skip or change your dose to manage skin symptoms on your own. Your prescriber decides whether a reaction calls for a dose change, a different medication or nothing at all.

Can skincare help Mounjaro skin sensitivity?

No topical product has been tested in people taking GLP-1 medications. That includes moisturizers, barrier creams and peptides. Our Oct 10, 2026 ClinicalTrials.gov search found no registered trial of any topical skincare product in GLP-1 users.

Dysesthesia is a sensory symptom, so a barrier-repair routine shouldn't be sold as its fix. Hypersensitivity and injection-site reactions are medical issues, and your prescriber should guide how they're handled.

A gentle, fragrance-free routine is a reasonable comfort choice for anyone whose skin feels reactive. It is general skincare, not a treatment for tirzepatide effects. Our hydration and barrier guide covers the basics, and our step-by-step routine order shows where each product goes. If new products sting, stop using them and mention it to your clinician, since ordinary contact irritation can happen to anyone. If you are tempted to reach for a body moisturizer instead, see whether body lotion is safe on your face.

Peptides such as GHK-Cu are general skincare ingredients with limited human evidence, and none has been studied for GLP-1-related changes. Our copper peptides explainer reviews what that evidence does and doesn't show.

If what's bothering you is facial volume rather than sensation, that's a separate issue tied to fat loss. See what actually helps with Ozempic face and our Wegovy face before-and-after evidence review.

Where the evidence stops

• No tirzepatide-specific dysesthesia trial. The detailed data on severity and resolution come from semaglutide (STEP UP), and that sponsor-reported breakdown isn't in the PubMed abstract.
• No mechanism. No published human study explains why GLP-1 or GIP/GLP-1 drugs cause skin burning or pain.
• No drug-to-drug comparison. No head-to-head trial compares skin symptoms on Mounjaro vs Ozempic, and FAERS counts can't answer that question.
• No barrier data. No study has measured skin barrier function or water loss through the skin in tirzepatide users.
• No topical trials. No skincare product, peptide or otherwise, has been tested in GLP-1 users.
• Hair loss cause unclear. Researchers haven't separated the effect of the drug from the effect of rapid weight loss.

FAQ

Is sensitive skin a listed side effect of Mounjaro? Yes, in several forms. The Mounjaro label lists hypersensitivity reactions (3.2% vs 1.7% placebo), injection-site reactions (3.2% vs 0.4%) and dysesthesia (0.4%), which covers burning or painful skin (Mounjaro label).

Why does my skin feel sunburned after my Mounjaro shot when there's no rash? Burning or soreness without a rash matches dysesthesia, a label-listed sensory reaction. In the semaglutide STEP UP trial it was mostly mild and usually resolved during treatment (Wharton et al., 2025). Tell your prescriber so they can track it.

Does Mounjaro skin sensitivity go away? For dysesthesia, sponsor-reported STEP UP data show about 86% of cases resolved while people stayed on semaglutide. Tirzepatide-specific data on duration aren't available. If hives, rash or injection-site reactions persist, your prescriber should assess them.

Is itchy skin from Mounjaro normal? Itching can be part of a hypersensitivity or injection-site reaction, and both are label-listed (Mounjaro label). Mild, short-lived itching at the injection site is different from widespread itching or hives, so report hives or a rash to your prescriber. Itching with swelling or trouble breathing is an emergency.

Will a barrier-repair or peptide routine fix Mounjaro skin sensitivity? No evidence says it will. No topical product has been tested in GLP-1 users, and dysesthesia is a sensory symptom, not a barrier problem. Gentle skincare can be a comfort choice, but it isn't a treatment.

Should I stop Mounjaro if my skin hurts? Never stop, skip or change a GLP-1 medication for skincare reasons. Talk to your prescriber first. Go to emergency care right away for swelling, trouble breathing or a rapidly spreading rash.

References

1. Eli Lilly and Company. MOUNJARO (tirzepatide) prescribing information, NDA215866, version effective 2026-07-29. FDA drug label; pooled placebo-controlled trial data and post-marketing reports. Retrieved via openFDA drug label API, Oct 10, 2026: https://api.fda.gov/drug/label.json?search=openfda.application_number:"NDA215866"
2. Eli Lilly and Company. ZEPBOUND (tirzepatide) prescribing information, NDA217806, version effective 2026-08-28. FDA drug label; SURMOUNT-1/-2 pooled placebo-controlled data. Retrieved via openFDA drug label API, Oct 10, 2026: https://api.fda.gov/drug/label.json?search=openfda.application_number:"NDA217806"
3. Novo Nordisk. WEGOVY (semaglutide) prescribing information, DailyMed SPL v19, PI revised 06/2026. FDA drug label; adult placebo-controlled weight-reduction trials and 7.2 mg trial. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
4. Wharton S, et al. Semaglutide 7.2 mg vs 2.4 mg vs placebo for obesity (STEP UP). Lancet Diabetes & Endocrinology. 2025. Phase 3b double-blind RCT, n=1,407, 72 weeks; sponsored by Novo Nordisk. https://pubmed.ncbi.nlm.nih.gov/40961952/
5. El-Amawy, et al. Tirzepatide and the skin: cutaneous adverse events and cosmetic implications. Anais Brasileiros de Dermatologia. 2026. Narrative review; funding not reported in the abstract. https://pubmed.ncbi.nlm.nih.gov/41483501/
6. Cheng, et al. GLP-1 receptor agonists and hair loss: a meta-analysis. Diabetes Research and Clinical Practice. 2026. Meta-analysis of 9 interventional studies (7 RCTs), n=4,114; no competing interests declared. https://pubmed.ncbi.nlm.nih.gov/42155605/
7. Daniel, et al. Cutaneous adverse events of GLP-1 receptor agonists in FAERS. Journal of Drugs in Dermatology. 2025. Pharmacovigilance review of 6 GLP-1 drugs including tirzepatide; funding not reported in the abstract. https://pubmed.ncbi.nlm.nih.gov/40196945/
8. US Food and Drug Administration. openFDA drug adverse event (FAERS) API, tirzepatide skin-related MedDRA terms. Queried Oct 10, 2026, 2:29 PM CT. https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:"TIRZEPATIDE"+AND+patient.reaction.reactionmeddrapt.exact:"Dysaesthesia"&limit=1

Disclosure: This article contains no affiliate links, and no brand funded or reviewed it. It is for general information only and is not medical advice. Peptide Skincare Editorial Team members are not your clinicians. Never stop, skip or change a GLP-1 medication for skincare reasons; talk to your prescriber first. If you have swelling of the face, lips or throat, or trouble breathing, seek emergency care.

For educational purposes only; not medical advice. See our disclaimer and research method.